



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APR 21 1999

Norman H. Stepno
Burns, Doane, Swecker & Mathis, L.L.P.
P.O. Box 1404
Alexandria, VA 22313-1404

Re: Patent Term Extension
Application for
U.S. Patent No. Re. 34,440

Dear Mr. Stepno:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. Re. 34,440 for a period of 433 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products).

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson
Senior Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy, Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: DIFFERIN Topical Gel
FDA Docket No.: 96E-0362

kt

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

PATENT NO. : Re. 34,440
ISSUED : November 9, 1993
INVENTOR(S) : Braham Shroot et al.
PATENT OWNER : Centre International de Recherches Dermatologiques
PRODUCT : DIFFERIN Gel (adapalene)

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

433 days

from March 24, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 16th day of April 1999.

A handwritten signature in black ink, appearing to read "Q. Todd Dickinson".

Q. Todd Dickinson
Acting Assistant Secretary of Commerce and
Acting Commissioner of Patents and
Trademarks



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APR 21 1999

Norman H. Stepno
Burns, Doane, Swecker & Mathis, L.L.P.
P.O. Box 1404
Alexandria, VA 22313-1404

Re: Patent Term Extension
Application for
U.S. Patent No. Re. 34,440

Dear Mr. Stepno:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. Re. 34,440 for a period of 433 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products).

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson
Senior Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy, Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: DIFFERIN Topical Gel
FDA Docket No.: 96E-0362

kt

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO. : Re. 34,440
ISSUED : November 9, 1993
INVENTOR(S) : Braham Shroot et al.
PATENT OWNER : Centre International de Recherches Dermatologiques
PRODUCT : DIFFERIN Gel (adapalene)

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

433 days

from March 24, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 16th day of April 1999.

A handwritten signature in black ink, appearing to read "Q. Todd Dickinson".

Q. Todd Dickinson

Acting Assistant Secretary of Commerce and
Acting Commissioner of Patents and
Trademarks